- Region:
- USA
- Category:
- Society
U.S. FDA authorizes Pfizer's COVID-19 booster for 12- to 15-year-olds
![The agency also shortened the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 vaccine and a booster dose to five months from six.]()
The FDA allowed for a third dose of vaccine in immunocompromised children 5 to 11 years of age. The agency also shortened the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 vaccine and a booster dose to five months from six.
The agency also shortened the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 vaccine and a booster dose to five months from six.
The Food and Drug Administration has authorized the use of a Pfizer-BioNTech booster in adolescents 12 to 15 years old.
The agency also shortened the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 vaccine and a booster dose to five months from six.
Finally, the FDA allowed for a third dose of vaccine in immunocompromised children 5 to 11 years of age.
The director of the Centers for Disease Control and Prevention, Rochelle Walensky, must still weigh in with a recommendation on the FDA's announcement before the changes can take effect.
"Throughout the pandemic, as the virus that causes COVID-19 has continuously evolved, the need for the FDA to quickly adapt has meant using the best available science to make informed decisions with the health and safety of the American public in mind," acting FDA Commissioner Janet Woodcock, M.D., said in a statement.
Woodcock said it is critical for the public to take "effective, life-saving preventative measures," including booster shots, during the current surge of infections driven by the omicron variant.
